Source comparison
MK-677 Deep Sleep Optimization: Research vs Supplement Product Comparison
Mechanism of Action Selective GHS-R1a agonist; increases pulsatile GH release Same active compound but variable purity (60–98%) GABA-A receptor modulation; suppresses wakefulness MK-677 uniquely targets GH-mediated sleep architecture. Not sedation Slow-Wave Sl
This comparison does not assign a generated winner or score.
- Mechanism of Action
- Selective GHS-R1a agonist; increases pulsatile GH release
- Same active compound but variable purity (60–98%)
- GABA-A receptor modulation; suppresses wakefulness
- MK-677 uniquely targets GH-mediated sleep architecture. Not sedation
- Slow-Wave Sleep Increase
- 35–50% increase in stage 4 sleep duration (clinical data)
- Effects proportional to purity and dose accuracy
- Increases total sleep time but suppresses SWS depth
- Research-grade MK-677 delivers measurable SWS increases; supplements depend on batch quality
- REM Sleep Impact
- REM latency +18 min; REM consolidation improved
- Consistent with research data if dosed correctly
- REM suppression (20–40% reduction in REM percentage)
- MK-677 preserves REM; GABA agonists do not
- Dosing Precision
- ±2% variance (pharmaceutical-grade synthesis)
- ±10–25% variance (third-party testing shows frequent under-dosing)
- Highly standardized (FDA-approved formulations)
- Dosing variability in supplements makes consistent results difficult
- Onset Time
- 90–120 minutes to peak plasma concentration
- Same pharmacokinetics if dose is accurate
- 15–30 minutes (faster onset but shorter duration)
- MK-677 requires advance timing; not a 'take and sleep immediately' compound
- Tolerance Development
- Observed after 8–12 weeks continuous use
- Same tolerance pattern
- Tolerance within 2–4 weeks (benzodiazepines)
- MK-677 tolerance is slower but still requires cycling
- Bottom Line
- Gold standard for GH-mediated deep sleep enhancement; requires sourcing from verified suppliers
- Effective if third-party tested for purity (≥98%); avoid under-dosed or contaminated products
- Fast-acting but alters natural sleep architecture; not equivalent to MK-677's mechanism
- Research-grade MK-677 from Real Peptides ensures dosing accuracy and purity. Critical for consistent sleep benefits
- The purity variance in supplement-grade MK-677 is the single biggest obstacle to replicating clinical trial results. Third-party testing consistently finds 15–30% of MK-677 products under-dosed or contaminated with related compounds like GHRP-6 or hexarelin. Those impurities don't necessarily harm sleep, but they alter the pharmacokinetic profile unpredictably. Making it impossible to dial in the timing and dosing precision required for optimal slow-wave sleep enhancement.